The U.S. Food and Drug Administration (FDA), on October 30, 2019, approved a new option in the treatment of multiple sclerosis (MS): Vumerity (diroximel fumarate), which is manufactured by the drugmaker Biogen. Continue reading →

STAINES-UPON-THAMES, United Kingdom, Nov. 7, 2019 /PRNewswire/ --Mallinckrodt plc(NYSE: MNK), a global biopharmaceutical company, today announced the publication of "Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population" in an electronic publicationposted in advance of print publication in the peer-reviewed journal Neurology and Therapy. Continue reading →

BALTIMORE, Nov. 7, 2019 /PRNewswire/ --Just three years after opening its doors, the Maryland Proton Treatment Center (MPTC) has reached a major milestone by treating its 2,000th patient.MPTC is the first proton treatment center to open in the District/Maryland/Virginia region. It is also the only treatment center in the world that offers both proton and thermal therapies in one facility Continue reading →

"We are excited to have reached this important milestone in the clinical evaluation of INXN-4001 for treatment of end-stage heart failure," stated Amit Patel, MD, MS, Co-Founder and Medical Director of TripleGene. "Heart failure rarely results from a single genetic defect, and while single gene therapy approaches have been studied, these treatments may not fully address the causes of the disease. Continue reading →

Still, as Mr. Couturier said: When Blass or anyone dropped her, she didnt say one word against them. Never ever. Continue reading →

SAN DIEGO--(BUSINESS WIRE)--CARLSMED, Inc., a San Diego-based medical technology company, today announced the appointment of Sharon Schulzki as Chief Operating Officer (COO). Ms. Schulzki has deep experience building venture backed MedTech startups and has excelled in prior executive leadership roles with market leaders Stryker and Johnson & Johnsons DePuy Synthes Continue reading →